There are contraindications! Be sure to consult your doctor before taking any medication!
Aerogastrol consists of Chlordiazepoxide, Metoclopramide, Simethicone.
Chlordiazepoxide - An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Indication: For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
Aerogastrol (Chlordiazepoxide) has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Aerogastrol (Chlordiazepoxide) revealed a "taming" action with the elimination of fear and aggression. The taming effect of Aerogastrol (Chlordiazepoxide) was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.
Metoclopramide - A dopamine D2 antagonist that is used as an antiemetic.
Indication: For the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying.
Aerogastrol (Metoclopramide), although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Aerogastrol (Metoclopramide) is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Aerogastrol (Metoclopramide) may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: